Willingness to pay for targeted therapy in ovarian cancer v1.0
Research type
Research Study
Full title
A cross sectional study of the willingness to pay for targeted therapy in advanced ovarian cancer
IRAS ID
332494
Contact name
Asima Mukhopadhyay
Contact email
Sponsor organisation
Jmaes Cook University Hospital. South Tees NHS Foundation Trust
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
Ovarian cancer (OC) causes a significant health and economic burden both at the individual and global level. Global Cancer Observatory reported 314,000 new diagnoses and 207,000 deaths attributed to OC in the year 2020 with the highest incidence observed in high income European countries. There is a projected increase in the burden of OC in low resource countries within the next two decades.
Poly (ADP-ribose) polymerase inhibitors (PARPi) used in the treatment of advanced OC provide an additional strategy beyond surgery and chemotherapy in the treatment of OC which can prolong survival. There is also evidence suggesting a longer duration of action of rucaparib (a drug in the class of PARP inhibitors), which suggests that a less frequent dosing regime is feasible and could be effective. Reduction in the dose could lead to less side effects, reduced costs and presents an opportunity to allow more women to access treatment whilst increasing survival without progression of the disease.
This study aims to determine the willingness to pay for twice weekly dosing of PARPi in comparison to the current standard of care (daily dosing of PARPi) in a group of participants aged 18 years and over with a diagnosis of ovarian cancer. The research question will be addressed via an online survey and interviewer administered questionnaire to determine the value of this treatment to women by the expression of their willingness to pay for it.REC name
London - Surrey Borders Research Ethics Committee
REC reference
23/PR/1429
Date of REC Opinion
20 Dec 2023
REC opinion
Further Information Favourable Opinion